ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / MTD / dividends
WAT (73) A (75) RVTY (68) AVTR (59) ⌘ Pro Terminal →

Mettler-Toledo International Inc. (MTD) Dividend Safety Gauge & 10-Year DRIP Compounder

$1,674.81 -2.55% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1,671.14

Mettler-Toledo International Inc. (MTD) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (59% profit margin, 30% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate) →
ROARABLE B+ • BUY Cap $34.44B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MTD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MTD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Mettler-Toledo International Inc. (NYSE: MTD) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $1,674.81 (-2.55% 1D, market cap $34.44B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, MTD ranks #26 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MTD compare to WAT and A in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), MTD carries a Roarable B+ (77/100 RQD), trailing P/E of 39.6x, gross margin of 59.4%, and ROIC of 30.4%. By comparison, WAT (Waters Corporation) holds a B grade (73/100 RQD, P/E 73.4x, ROIC 16.8%, cap $47.17B) and A (Agilent Technologies Inc.) posts a B grade (75/100 RQD, P/E 39.2x, ROIC 15.3%, cap $51.07B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MTD?
▼

Per MTD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001037646), Mettler-Toledo International Inc. generated $4.03B in revenue (+4.0% YoY), $869.2M in net income, and $848.6M in free cash flow against $3.71B in total assets and $2.09B in total debt. Key quantitative strengths: Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 40x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1,671.13 (-0.22%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 21.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B+
025507510077
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B
Cash (18)Whales (18)SEC (16)Macro (13)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+8.6% Base Target
$2145 Bull$1818 Base$1373 Bear
📬 FREE MTD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MTD)Realized 20D OHLCV Swing Band: ±4.9%
Deterministic 5-Pillar Attribution (77/100 Composite)
🔍 WHY MTD SCORES 77/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 21.1% FCF Margin ($848.6M FCF) & 59.4% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+18/20 pts (23% of score)

20D Institutional Volume Accumulation (±4.9% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
69
Grade B-$1,598.03+2.3% Next Q
Q2 (-2Q)
72
Grade B$1,634.01+3.1% Next Q
Q3 (-1Q)
74
Grade B+$1,685.32-0.6% Next Q
Current
77
Grade B+$1,674.81+7.8% Hist 90D α
Trajectory: B- (69) → B+ (77)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MTD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 77/100 (B+) score, MTD faces multiple-compression risk if 39.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 40x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 56.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1,506.92) or 200D SMA ($1,339.89) invalidates the momentum regime and cuts Target Base ($1,818.01) toward Bear Floor ($1,373.34).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MTD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MTD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 77%NO 23%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in MTD & A-Rated Leaders

  • ✓12-month Bull/Base/Bear fair-value walkthrough on MTD and its top sector peer
  • ✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
  • ✓Includes nightly RQD rating-change & forensic signal email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MTD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +32.86%▲ ASCENDING CHANNEL
2026-11-02O $1,698.5H $1,718.6L $1,674.8C $1,674.8VOL 129.6K
RES: $1,741.4SUP: $1,360.1SMA50: $1,506.9SMA200: $1,339.9
$1,778.1$1,573.4$1,368.8$1,164.2$959.5RES $1,741.4SUP $1,360.1$1,674.82026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MTD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MTD Butterfly Map → + Track MTD →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
30.2%/yr Implied 5Y Growth

vs. +4.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MTD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MTD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MTD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MTD)

Health Care Rank #26 of 1016 ⚔️ WAT vs MTD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MTD vs. WAT, A, RVTY, AVTR)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Mettler-Toledo International Inc. (MTD) ranks #26 by composite RQD confidence (77/100, grade B+) and #54 by equity capitalization ($34.44B). Within this direct 5-issuer industry benchmark cohort, A leads on earnings valuation at 39.2x trailing P/E, while MTD leads on capital efficiency and profitability with 30.4% ROIC and 59.4% gross margin. MTD currently leads its immediate peer cohort in composite quantitative strength at 77/100 (B+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MTD ACTIVE
Mettler-Toledo International Inc.
B+ 77/100 39.6x 59.4% 30.4% -2.55% $34.44B Benchmark Subject
WAT
Waters Corporation
B 73/100 73.4x 59.3% 16.8% -3.61% $47.17B /wat-vs-mtd →
A
Agilent Technologies Inc.
B 75/100 39.2x 52.4% 15.3% -3.47% $51.07B /a-vs-mtd →
RVTY
Revvity Inc.
C+ 68/100 76.7x — 3.1% -5.30% $18.50B /rvty-vs-mtd →
AVTR
Avantor Inc.
C- 59/100 — 32.7% -2.1% -3.78% $11.30B /avtr-vs-mtd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001037646

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mettler-Toledo International Inc. (MTD) reported GAAP revenue of $4.03B (+4.0% vs. FY2024 revenue of $3.87B , and +6.3% cumulative change since FY2023) , GAAP net income of $869.2M, operating cash flow of $955.8M, and free cash flow of $848.6M (-1.8% YoY). On the balance sheet, MTD closed FY2025 with $3.71B in total assets against $2.09B in total debt (Altman Z-Score: 11.09, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $4.03B $869.2M $955.8M $848.6M $3.71B $2.09B
FY2024 (FY) 2024-12-31 $3.87B $863.1M $968.3M $864.4M $3.24B $1.83B
FY2023 (FY) 2023-12-31 $3.79B $788.8M $965.9M $795.4M $18.94B $4.43B

3. MTD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MTD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Mettler-Toledo International Inc. (NYSE: MTD) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $1,674.81 (-2.55% 1D, market cap $34.44B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, MTD ranks #26 in composite RQD confidence.

How does MTD compare to WAT and A in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), MTD carries a Roarable B+ (77/100 RQD), trailing P/E of 39.6x, gross margin of 59.4%, and ROIC of 30.4%. By comparison, WAT (Waters Corporation) holds a B grade (73/100 RQD, P/E 73.4x, ROIC 16.8%, cap $47.17B) and A (Agilent Technologies Inc.) posts a B grade (75/100 RQD, P/E 39.2x, ROIC 15.3%, cap $51.07B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MTD?

Per MTD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001037646), Mettler-Toledo International Inc. generated $4.03B in revenue (+4.0% YoY), $869.2M in net income, and $848.6M in free cash flow against $3.71B in total assets and $2.09B in total debt. Key quantitative strengths: Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 40x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MTD trading relative to its 50-day, 200-day, and 52-week technical levels?

MTD last traded at $1,674.81 (-2.55% on volume of 189,705 shares), positioning the stock +11.14% above its 50-day simple moving average ($1,506.92) and +25.00% above its 200-day simple moving average ($1,339.89). Across its 52-week range of $1,023.05 to $1,728.66, MTD sits at the 92.4% percentile with a 14-day RSI of 70.6 (OVERBOUGHT (>70)) and an implied next-earnings move of ±4.9% ($1,592.74 to $1,756.88).

MTD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does MTD pay a dividend and is it safe?

Mettler-Toledo International Inc. (MTD) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: MTD RQD Cockpit MTD 12M Forecast MTD Earnings & Move MTD Dividends & DRIP MTD Insiders & 13F MTD Whale Options MTD Profit Sankey MTD News & Why
ROARABLE RATING BRIEF • RQD 77/100 (B+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MTD — Mettler-Toledo International Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:12:06Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MTD scores 77 out of 100, graded B+, labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:

  • Fundamental Cash Engine: 18 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 30.4% and an FCF yield of 2.46%. For a prospective investor, the high return on invested capital indicates strong capital efficiency, while the low FCF yield signals that the stock is priced at a rich multiple of current free cash flow. Upside depends on sustained cash generation; the valuation tradeoff is that much of the growth is already reflected in price.
  • Whale 13F Flow: 18 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. Institutional demand is a supportive technical and sentiment factor, though the underlying holder detail is not provided in the source data.
  • Insider Conviction: 12 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. This is a moderate reading, indicating neither strong insider buying conviction nor a clear warning signal.
  • Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, beta is 0.87, indicating the stock has historically moved less than the broad market. This offers some defensiveness in volatile regimes, but the sector-sensitivity component limits the score.
  • Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, the Altman Z-Score is 11.09, Piotroski F-Score is 8/9, and Debt/Equity is 0.85. These readings point to a financially sound balance sheet with low distress risk.

Taken together, the rating points to a high-quality compounder with strong capital returns and balance sheet health, offset by a premium valuation (P/E TTM of 39.6) that leaves limited margin for error if growth slows.

Snapshot

MetricValue
Price1718.61
Market Cap$34.44B
P/E (TTM)39.6
Forward P/E36.8
EV/EBITDA31.7
EPS (TTM)43.38
Dividend Yield0%
Beta0.87
52-Wk Range$1023.05 - $1728.66
ROIC %30.4%

Business

Mettler-Toledo International Inc. is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Laboratory Analytical Instruments industry, per the profile. The source data does not itemize its products, customer categories, or revenue mix. Per the SEC financials, the company generated revenue of $4026.4M in FY 2025, indicating a sizable operating business. The source data does not describe how the company monetizes its offerings beyond these reported financial results.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$4026.4M$1025.6M$869.2MN/A$848.6M$66.9M$2088.2M
FY 2024$3872.4M$1018.5M$863.1MN/A$864.4M$59.4M$1831.3M
FY 2023$3788.3M$930.8M$788.8MN/A$795.4MN/A$4431.8M

Per the SEC financials, revenue grew from $3788.3M in FY 2023 to $4026.4M in FY 2025, with net income rising over the same span. Per the market data, gross margin is 59.4%, operating margin 26.3%, and net margin 21.6%, with ROIC at 30.4%. Per the Roarable RQD rating, the Altman Z-Score is 11.09 and the Piotroski F-Score is 8/9, both consistent with strong financial health. Debt/Equity is 0.85 per the Roarable RQD rating, and reported debt moved from $4431.8M in FY 2023 to $2088.2M in FY 2025.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section:

  • A Seeking Alpha piece (YELLOW) argues the shares are still too pricey.
  • A Yahoo Finance item (YELLOW) announces an investor meeting.
  • A TradingView item (GREEN, CATALYST) reports a 12-month price target raised to $1544.42.
  • A Yahoo Finance item (YELLOW) reports JPMorgan adjusting its price target to $1,550 from $1,400.
  • A MarketBeat item (YELLOW) reports Robeco Schweiz AG lessening its position.
  • A Simply Wall St item (YELLOW) suggests the stock could be 9% above fair value as momentum builds.

Risk watch items include valuation concerns and the 9% above-fair-value estimate. Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Open Questions

  • What are the company's specific products, end markets, and revenue mix, given that the source data only provides the sector and industry classification?
  • What is the reported EPS for FY 2024 and FY 2025, since the source data lists EPS as N/A?
  • What is the cash balance for FY 2023, and what drove the change in debt between FY 2023 and FY 2025?
  • What is the current analyst consensus and holder composition, since both sections are empty in the source data?
  • How does the current price of 1718.61 compare with the individual price targets cited in the news wire, and which assumptions underpin them?

MTD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Mettler-Toledo International Inc. (MTD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MTD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MTD Bull vs. Bear Conversation Board — What's Your Call at $1,674.81?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MTD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MTD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $2,027.96 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MTD (B+ • RQD 77/100) a Buy at $1718.61?

Welcome to the MTD (Mettler-Toledo International Inc.) Roar Pit. Current RQD Composite is 77/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Biotechnology: Laboratory Analytical Instruments. Bulls point to capital efficiency (30.4% ROIC), while bears focus on valuation multiple compression (39.6x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1,409.26 (-18.0%)
Spot @ $1,718.61

Pump the brakes on MTD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MTD, but look at what you are paying: 39.6x trailing P/E with 59.4% gross margins. Unless Mettler-Toledo International Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2,165.45 (+26.0%)
Spot @ $1,718.61

MTD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MTD, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $1718.61 (52-wk range $1023.05 - $1728.66), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%